arrow
M

Marco Puthenparampil

University of Padua
H指数:21
被引数:1,351

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcomes of alemtuzumab in relapsing–remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab

来那度胺在复发-缓解型多发性硬化中的长期结局:一项真实世界队列研究,重点关注natalizumab治疗后的治疗顺序

2026-10-080
OA
EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patients

EDSS评分和病程与进展相关,且与纳武利尤单抗治疗的多发性硬化患者中的复发和MRI活动无关

2026-05-010
OAAI
Retrospective In Silico Analysis of Routine Laboratory Data Supports a Specific Association of Epstein-Barr Virus and Multiple Sclerosis

回顾性计算机分析常规实验室数据支持EB病毒与多发性硬化之间的特定关联

2025-11-010
OAAI
Organisational impact and patient management models for biomarker integration in multiple sclerosis care in Italy: the 0Tolerance project

组织影响及意大利多发性硬化护理中生物标志物整合的患者管理模型:0Tolerance项目

2025-10-090
OA
Neuropsychological awareness in pediatrics (NAP): Proposal of a new cognitive self-report questionnaire for pediatric multiple sclerosis patients

神经心理学意识在儿科(NAP):为儿科多发性硬化患者提出一个新的认知自评问卷

2025-02-010
PRE
Blood biomarkers for Alzheimer's disease with the Lumipulse automated platform: Age-effect and clinical value interpretation

使用Lumipulse自动化平台的阿尔茨海默病血液生物标志物: 年龄效应和临床价值解释

2025-01-010
OAAI
Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics
2024-10-010
OAAI
Proteomic profile of extracellular vesicles from plasma and CSF of multiple sclerosis patients reveals disease activity-associated EAAT2

多发性硬化症患者血浆和CSF细胞外囊泡的蛋白质组学特征揭示了与疾病活动相关的EAAT2

2024-09-020
OAAI
Sars-CoV2 infection in pregnant women with multiple sclerosis

多发性硬化症孕妇的Sars-CoV2感染

2023-05-261
OA